Please login to the form below

Not currently logged in
Email:
Password:

HTA guidance from NICE, the SMC and the AWMSG

Here we present a feed of upcoming health technology assessment (HTA) decisions, covering appraisals by the National Institute of Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC) and the All Wales Medicines Strategy Group (AWMSG).

Provided by Guidelines, it also features: NICE clinical guidelines, NICE quality standards, NICE evidence updates, NICE evidence summaries, independent professional body guidelines and (Scottish Intercollegiate Guidelines Network (SIGN) guidance.

NICE managing COVID-19 guideline

Summary of NICE guidance on the management of COVID-19 in children, young people, and adults in primary care settings
Published: 27 Jun 2022

UKHSA monkeypox guidance

Providing information and advice for healthcare professionals on monkeypox. Includes vaccination recommendations and a useful contact tracing table
Published: 21 Jun 2022

Best practice treatment and management of patients with type 2 diabetes, cardiovascular disease, and heart failure

This management algorithm was developed by a multidisciplinary expert panel: Javaid et al with the support of an educational grant from AstraZeneca. Information intended for UK healthcare professionals.
Published: 20 May 2022

NICE epilepsies guideline

Covering diagnosing and managing epilepsy in children, young people, and adults
Published: 13 May 2022

NHS statin intolerance pathway

A Guidelines summary covering the definition, classification, and management of statin intolerance
Published: 04 May 2022

UKHSA HPV vaccination guidance

Summary of adolescent and MSM HPV vaccination guidance with updated (March 2022) recommendations on dosing
Published: 04 May 2022

Visit the Guidelines website

NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia

NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia 1 Jul 2022
The National Institute for Health and Care Excellence (NICE) has issued a final draft recommendation for Novartis Pharmaceuticals UK’s Scemblix (asciminib) for patients with Philadelphia chromosome-positive chronic myeloid leukaemia ... NICE’s

NICE issues final appraisal recommending LEO Pharma’s Adtralza for moderate-to-severe atopic dermatitis

NICE issues final appraisal recommending LEO Pharma’s Adtralza for moderate-to-severe atopic dermatitis 30 Jun 2022
The decision from NICE follows a multiple technology appraisal (MTA) and its recommendation simultaneously approves Adtralza, Rinvoq (upadacitinib) and Cibinqo (abrocitinib) for reimbursement following use in NHS England and Wales, which ... NICE based

Eli Lilly’s Verzenios recommended by NICE as combination therapy for early-stage breast cancer

Eli Lilly’s Verzenios recommended by NICE as combination therapy for early-stage breast cancer 17 Jun 2022
Eli Lilly’s Verzenios (abemaciclib) has been recommended by the National Institute for Health and Care Excellence (NICE) as a treatment for early-stage breast cancer in combination with endocrine therapy. ... The NICE approval of Verzenios in

NICE recommends Vazkepa for patients at risk of stroke and heart attacks in England and Wales

NICE recommends Vazkepa for patients at risk of stroke and heart attacks in England and Wales 10 Jun 2022
Amarin’s Vazkepa (icosapent ethyl) has been recommended by the National Institute for Health and Care Excellence (NICE) for adults receiving statin treatment who are deemed to be at high cardiovascular ... Vazkepa is a new active substance, made up of

NICE recommends Sanofi and Regeneron’s Libtayo for advanced CSCC

NICE recommends Sanofi and Regeneron’s Libtayo for advanced CSCC 26 May 2022
NICE’s decision was based on positive results from the EMPOWER-CSCC-1 trial. ... NICE first recommended that Libtayo should be made available through the Cancer Drugs Fund (CDF) in 2019.

More news from PMLiVE on NICE, the SMC and the AWMSG

MGP’s Guidelines brand is trusted by over 58,000 healthcare professionals for concise clinical summaries of major primary and shared care guidelines in the UK. Through Guidelines, Guidelines for Nurses and Guidelines in Practice, MGP connect pharmaceutical and medical device companies to an engaged audience of GPs, GP commissioners and payers, nurses and allied healthcare professionals.

To discuss how we can support your guidance or implementation needs please contact marketing@mgp.co.uk

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Mednet Group

PMEA Agency of the year 2021. With diversity and inclusion at our core, Mednet Group consists of Attigo CIC and...